PODD

Over the past six months, Insulet Corp. (PODD) stock experienced a -57.49% decrease over the last year as of October 10, 2026. In Q1 2026 (May), Insulet reported robust revenue growth and adjusted EPS exceeding estimates, driven by Omnipod 5 adoption, but the market responded negatively due to seasonality concerns and a voluntary medical device correction. In Q2 2026 (August 5), strong results with revenue of $801.7 million and EPS of $1.66 surpassed estimates, yet the stock dropped significantly (around 20.1%) due to weaker-than-expected Type 2 diabetes patient retention, leading to lowered full-year 2026 U.S. revenue growth guidance. Following Q2 earnings and revised guidance, several analysts downgraded Insulet's stock and cut price targets on August 6, 2026. The stock's 52-week high was $354.88, and its 52-week low was $126.40, opening at $134.36 on October 8, 2026. Insulet is scheduled to announce its Q3 2026 financial results on November 4, 2026. In October 2026, Barclays upgraded Insulet to 'Hold', and Wall Street Zen upgraded it from 'Hold' to 'Buy'.